Last Posted: Sep 16, 2021
- [Current developments in hemostatic treatment for patients with hemophilia].
Nogami Keiji et al. [Rinsho ketsueki] The Japanese journal of clinical hematology 2021 62(8) 1213-1221
- A qualitative study on the experiences of haemophilia carriers before, during and after pregnancy.
Punt Marieke C et al. Haemophilia : the official journal of the World Federation of Hemophilia 2021
- Cost-effectiveness Analysis of Prophylaxis Versus On-demand Treatment for Children With Hemophilia B Without Inhibitors in China.
Liu Guoqing et al. Clinical therapeutics 2021
- Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A.
Pasi K John et al. Haemophilia : the official journal of the World Federation of Hemophilia 2021
- Patient preferences and priorities for haemophilia gene therapy in the US: A discrete choice experiment.
Witkop Michelle et al. Haemophilia : the official journal of the World Federation of Hemophilia 2021
- Gene therapy for hemophilia: Current status and laboratory consequences.
Batty Paul et al. International journal of laboratory hematology 2021 43 Suppl 1117-123
E Berntorp et al, Nature Dis Primers., June 24, 2021
- Prediction of hemophilia A severity using a small-input machine-learning framework.
Lopes Tiago J S et al. NPJ systems biology and applications 2021 7(1) 22
- Patterns of joint damage in severe haemophilia A treated with prophylaxis.
Goren Rachel et al. Haemophilia : the official journal of the World Federation of Hemophilia 2021
- Optimizing language for effective communication of gene therapy concepts with hemophilia patients: a qualitative study.
Hart Daniel P et al. Orphanet journal of rare diseases 2021 16(1) 189
- Gene therapy may not be as expensive as people think: challenges in assessing the value of single and short-term therapies.
Garrison Louis P et al. Journal of managed care & specialty pharmacy 2021 27(5) 674-681
- Data from CDC’s hemophilia surveillance programs can help prevent or reduce hemophilia-related health problems
CDC, March 2021
- Health care resource utilization and costs among adult patients with hemophilia A on factor VIII prophylaxis: an administrative claims analysis.
Croteau Stacy E et al. Journal of managed care & specialty pharmacy 2021 27(3) 316-326
- Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH.
Konkle Barbara et al. Journal of thrombosis and haemostasis : JTH 2020 Nov 18(11) 3074-3077
- Current Clinical Applications of in vivo Gene Therapy with AAVs.
Mendell Jerry R et al. Molecular therapy : the journal of the American Society of Gene Therapy 2020 Dec
- Assessing the current knowledge, attitude and behaviour of adolescents and young adults living with haemophilia.
Mohan Richa et al. Haemophilia : the official journal of the World Federation of Hemophilia 2020 Dec
- Addressing patient education priorities in the era of gene therapy for haemophilia: Towards evidence-informed shared decision-making.
Woollard Laurence et al. Haemophilia : the official journal of the World Federation of Hemophilia 2020 Nov
- Reimbursing the value of gene therapy care in an era of uncertainty.
Noone Declan et al. Haemophilia : the official journal of the World Federation of Hemophilia 2020 Nov
- Evaluation of anti-factor VIII antibody levels in patients with haemophilia A receiving immune tolerance induction therapy or bypassing agents.
Boylan Brian et al. Haemophilia : the official journal of the World Federation of Hemophilia 2020 Nov
- Patient perspectives regarding gene therapy in haemophilia: Interviews from the PAVING study.
van Overbeeke Eline et al. Haemophilia : the official journal of the World Federation of Hemophilia 2020 Nov
- Insights from the Hereditary Thrombotic Thrombocytopenic Purpura Registry: Discussion of Key Findings Based on Individual Cases from Switzerland.
Kremer Hovinga Johanna A et al. Hamostaseologie 2020 Nov 40(S 01) S5-S14
- Novel F8 and F9 gene variants from the PedNet Hemophilia Registry classified according to ACMG/AMP guidelines.
Andersson Nadine G et al. Human mutation 2020 Sep
- Treatment preferences in people with haemophilia A or caregivers of people with haemophilia A: A discrete choice experiment.
Fifer Simon et al. Haemophilia : the official journal of the World Federation of Hemophilia 2020 Aug 26 Suppl 530-40
- Evaluation of CDC's Hemophilia Surveillance Program - Universal Data Collection (1998-2011) and Community Counts (2011-2019), United States.
Schieve Laura A et al. Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C. : 2002) 2020 Sep (5) 1-18
- BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A.
Konkle Barbara A et al. The New England journal of medicine 2020 Sep (11) 1018-1027
- Prevalence of FVIII Inhibitors Among Children with Hemophilia A: Experience at the Jordanian Royal Medical Services.
Oudat Raida et al. Medical archives (Sarajevo, Bosnia and Herzegovina) 2020 Jun 74(3) 187-190
- Beliefs and Values About Gene Therapy and In-Utero Gene Editing in Patients with Hemophilia and Their Relatives.
Vasquez-Loarte Tania C et al. The patient 2020 Aug
- Gene therapy for hemophilia: anticipating the unexpected.
Pierce Glenn F et al. Blood advances 2020 Aug 4(15) 3788
- CRISPR/Cas9-mediated gene correction in hemophilia B patient-derived iPSCs.
Morishige Satoshi et al. International journal of hematology 2020 Feb 111(2) 225-233
- How I manage pregnancy in carriers of hemophilia and patients with von Willebrand disease.
Leebeek Frank W G et al. Blood 2020 Aug
Rare Disease PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other information that address the public health impact and translation of genomic and other precision health discoveries into improved health outcomes related to rare diseases...more
- CDC Information (18)
- NIH Information (8)
- COVID-19 (20)
- CDC Publications (12)
- Human Genome Epidemiologic Studies (152)
- Genomic Tests Evidence Synthesis (7)
- Genomic Tests Guidelines (5)
- Tier-Classified Guidelines (4)
- Pathogen Advanced Molecular Detection (2)
- State Public Health Genomics Programs (7)
- Reviews/Commentaries (73)
- Tools/Methods (3)
- Ethical/Legal and Social Issues (ELSI) (4)
Selected Rare Diseases
- Alpha-1 Antitrypsin Deficiency
- Amyotrophic Lateral Sclerosis
- Brugada Syndrome
- Cerebral Palsy
- Cystic Fibrosis
- Duchenne Muscular Dystrophy
- Erythema Multiforme
- Familial Mediterranean Fever
- Fragile X Syndrome
- Gaucher Disease
- Graves Disease
- Huntington Disease
- Myasthenia Gravis
- Retinitis Pigmentosa
- Severe Combined Immunodeficiency
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.